Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program.
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Obesity negatively impacts patients’ health-related quality of life (QOL) and is associated with a range of complications such as type 2 diabetes (T2D), cardiovascular disease, and sleep apnea, alongside decreased physical function, mobility, and control of eating. The Semaglutide Treatment Effect in People with obesity (STEP) trials compared once-weekly subcutaneous semaglutide 2.4 mg with placebo in adults with overweight or obesity, with or without T2D. This article reviews the effects of semaglutide 2.4 mg on QOL, control of eating, and body composition. Weight-related QOL was assessed using the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT), and health-related QOL was assessed with the 36-item Short Form Health Survey version 2 (SF-36v2®). Control of eating was evaluated using the Control of Eating questionnaire in a subgroup of participants in one trial. Body composition was evaluated via dual-energy x-ray absorptiometry in another trial, in a subgroup of participants with a body mass index of ≤40 kg/m2. All IWQOL-Lite-CT scores (Physical Function, Physical, Psychosocial, and Total Score) improved with semaglutide 2.4 mg significantly more than with placebo. Across the trials, changes in SF-36v2 scores were generally in favor of semaglutide versus placebo. There were significant improvements in all Control of Eating questionnaire domains (craving control, craving for savory, craving for sweet, and positive mood) up to week 52 with semaglutide treatment versus placebo, with improvements in craving control and craving for savory remaining significantly different at week 104. Body composition findings showed that reductions in total fat mass were greater with semaglutide versus placebo. These findings highlight the wider benefits that patients can experience with once-weekly subcutaneous semaglutide 2.4 mg, in addition to weight loss, including improvements in patients’ wellbeing and ability to perform daily activities. Taken together, these are important considerations for primary care when incorporating pharmacotherapy for weight management.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A study that randomized adults who achieved ≥5% weight loss with a 12-week ILI before taking tirzepatide vs placebo found that those who added tirzepatide lost an additional 18.4% of their initial weight by week 72, vs. regain of 2.5% in the placebo group, leading to a total weight loss from start of intervention of 24.3% with tirzepatide vs 4.5% with placebo.77”
From Approach to Obesity Treatment in Primary Care: A Review (2024) · cites this paper as [77]
In the citing paper
“RCTs [75][76][77] suggest weight-loss efficacy greater than GLP1-RAs, with mean weight loss of ≈20% (placebo-subtracted ≈18%) in adults without T2D, and 36% losing ≥25% of initial weight.”
From Approach to Obesity Treatment in Primary Care: A Review (2024) · cites this paper as [77]
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 11×
“9%, respectively), as well as in T2D status (excluded in STEP 1 and required in STEP 2) [31,34].”
InfluentialThe Stigma of Obesity: A Review and Update
Puhl, R. M., & Heuer, C. A. (2009) · Obesity · doi:10.1038/oby.2008.636 · Cited by 3,323 · cited 1×
“for both mental and physical health [6,15].”
Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project
Ware, J. E., & Gandek, B. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00081-x · Cited by 2,605 · cited 2×
“formed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10, with higher scores representing better health-related QOL [40,41].”
Adipose Tissue, Inflammation, and Cardiovascular Disease
Berg, A. H., & Scherer, P. E. (2005) · Circulation Research · doi:10.1161/01.res.0000163635.62927.34 · Cited by 2,113
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Bray, G. A., Kim, K. K., Wilding, J. P. H., & on behalf of the World Obesity Federation (2017) · Obesity Reviews · doi:10.1111/obr.12551 · Cited by 1,612
Long-term persistence of hormonal adaptations to weight loss
Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105816 · Cited by 1,449 · cited 2×
“While some studies suggest that weight loss interventions can increase appetite, hunger, and craving [22,56], most suggest decreases in those phenomena with such interventions [56–58].”
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444 · cited 1×
“4 mg for a 20-week run-in period, then were randomized at week 20 (baseline) to continue treatment with semaglutide or were switched to placebo for the remaining 48 weeks [32].”
Self-citationDavies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419 · cited 8×
“9%, respectively), as well as in T2D status (excluded in STEP 1 and required in STEP 2) [31,34].”
InfluentialWadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114 · cited 1×
“4 mg or placebo for 68 weeks in STEP 1–3 [31,33,34] and for 104 weeks in STEP 5 [35].”
Self-citation
Research works printed but not linked: 6
- Blomain ES, 2013, ISRN Obes, 2013, 210524
- Garvey TW, 2021, Abstract presented at the 39th Annual Meeting of the Obesity Society at ObesityWeek® [Oral 096]
- Wharton S, 2021, Abstract presented at the 39th Annual Meeting of the Obesity Society at ObesityWeek® [Oral 095]
- Maruish ME, 2011, QualityMetric Inc.
- Rubino DM, 2021, Obes Facts, 14, 1, 10.1159/000509134 · DOI
- Rubino D, Presentation at the 81st Scientific Sessions of the American Diabetes Association
Cited by
Approach to Obesity Treatment in Primary Care: A Review
Yanovski, S. Z., & Yanovski, J. A. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.8526 · Cited by 103
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
Salvador, R., Moutinho, C. M. S. G., Sousa, C., Vinha, A. F., Carvalho, M. C., & Matos, C. M. (2025) · Pharmaceuticals · doi:10.3390/ph18030399 · Cited by 55
Gudzune, K. A., Stefanski, A., Cao, D., Mojdami, D., Wang, F., Ahmad, N., & Ling Poon, J. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16046 · Cited by 51
Mental Health Implications of Weight Loss Medications: A Narrative Review
Harding, S. (2024) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2024.105207 · Cited by 44
The effect of obesity pharmacotherapy on body composition, including muscle mass
Argyrakopoulou, G., Gitsi, E., Konstantinidou, S. K., & Kokkinos, A. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01533-3 · Cited by 28
“STEP trials 1, 2, 4, and 5 involved daily recommendations of a 500-calorie reduction and 150 min of physical activity, while STEP 3 encouraged intensive behavioral therapy with a low-calorie diet [43].”
Metadata
- Authors
- O’Neil, P. M., & Rubino, D. M.
- Affiliations
- Weight Management Center, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA
- Washington Center for Weight Management and Research (US)
- Corresponding author
- Rubino, Domenica M.
- Venue
- Postgraduate Medicine
- Publisher
- Informa UK Limited
- Published
- 2022-04-14
- Volume
- 134
- Issue
- sup1
- Pages
- 28-36
- ISSN
- 0032-5481 (ISSN-L)
- 1941-9260
- OpenAlex
- W4317871309
- Cited by
- 19
- References
- 54
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 7 · 2023: 1
- FWCI
- 0.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Postgraduate Medicine (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk Inc
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- semaglutide, obesity, weight management, health-related quality of life, weight-related quality of life, food intake regulation, body composition, fat mass reduction, type 2 diabetes, STEP program, primary care
- MeSH terms
- Semaglutide, Adult, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Obesity, Quality of Life
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program. https://app.cochat.ai/papers/10.1080/00325481.2022.2150006
- The paper
- O’Neil, P. M., & Rubino, D. M. (2022). Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program. Postgraduate Medicine. https://doi.org/10.1080/00325481.2022.2150006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.